Bon appetit: Cellectis CEO Choulika hosts a gene-edited feast; CRO Medpace adding 650 staffers
Cellectis CEO André Choulika loves nothing better than celebrating the pioneering work he’s planning to do with gene editing and next-gen CAR-T. But he also …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.